Aripiprazole in the treatment of obsessive compulsive disorder and aggressive behaviors in a child with prader willi syndrome

Journal of Clinical Psychopharmacology

Volumn 36, Issue 5, 2016, Pages 526-528

  Akça, Ömer Faruk ^a   Yilmaz, Savaş ^a  

^a NECMETTIN ERBAKAN UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; FLUOXETINE; SERTRALINE; NEUROLEPTIC AGENT;

AGGRESSION; CASE REPORT; CHILD; CLINICAL GLOBAL IMPRESSION SCALE; DISEASE SEVERITY; DRUG DOSE INCREASE; FEMALE; HUMAN; INTELLECTUAL IMPAIRMENT; LETTER; OBSESSIVE COMPULSIVE DISORDER; PRADER WILLI SYNDROME; PRIORITY JOURNAL; SCHOOL CHILD; SYMPTOMATOLOGY; TREATMENT DURATION; TREATMENT RESPONSE; COMPLICATION; DRUG EFFECT;

AGGRESSION; ANTIPSYCHOTIC AGENTS; ARIPIPRAZOLE; CHILD; FEMALE; HUMANS; OBSESSIVE-COMPULSIVE DISORDER; PRADER-WILLI SYNDROME;

EID: 84981724462     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0000000000000566     Document Type: Letter

References (14)

1. Holsen L, Thompson T. Compulsive behavior and eye blink in Prader-Willi syndrome: neurochemical implications. Am J Ment Retard. 2004;109:197-207.
2. Miller JL, Angulo M. An open-label pilot study of N-Acetylcysteine for skin-picking in Prader-Willi syndrome. Am J Med Genet A. 2014;164A:421-424.
3. Griggs JL, Sinnayah P, Mathai ML. Prader-Willi syndrome: from genetics to behaviour, with special focus on appetite treatments. Neurosci Biobehav Rev. 2015;59: 155-172.
4. Fleischhacker WW. Aripiprazole. Expert Opin Pharmacother. 2005;6:2091-2101.
5. Stahl SM. Stahls Essential Psychopharmacology: Neuroscientific Basis and Practical Application. 4th ed. New York: Cambridge University Press; 2013.
6. Comai S, Tau M, Pavlovic Z, et al. The psychopharmacology of aggressive behavior: a translational approach: part 2: clinical studies using atypical antipsychotics, anticonvulsants, and lithium. J Clin Psychopharmacol. 2012;32: 237-260.
7. Ji N, Findling RL. An update on pharmacotherapy for autism spectrum disorder in children and adolescents. Curr Opin Psychiatry. 2015;28:91-101.
8. Zuddas A, Zanni R, Usala T. Second generation antipsychotics (SGAs) for non-psychotic disorders in children and adolescents: a review of the randomized controlled studies. Eur Neuropsychopharmacol. 2011;21:600-620.
9. Deb S, Farmah BK, Arshad E, et al. The effectiveness of aripiprazole in the management of problem behaviour in people with intellectual disabilities, developmental disabilities and/or autistic spectrum disorder-A systematic review. Res Dev Disabil. 2014;35:711-725.
10. Selvi Y, Atli A, Aydin A, et al. The comparison of aripiprazole and risperidone augmentation in selective serotonin reuptake inhibitor-refractory obsessive-compulsive disorder: a single-blind, randomised study. Hum Psychopharmacol. 2011;26:51-57.
11. Veale D, Miles S, SmallcombeN, et al. Atypical antipsychotic augmentation in SSRI treatment refractory obsessive-compulsive disorder: a systematic review and meta-Analysis. BMC Psychiatry. 2014;14:317.
12. Ercan ES, Ardic UA, Ercan E, et al. A promising preliminary study of aripiprazole for treatment-resistant childhood obsessive-compulsive disorder. J Child Adolesc Psychopharmacol. 2015;25: 580-584.
13. Connor KM, Payne VM, Gadde KM, et al. The use of aripiprazole in obsessive-compulsive disorder: preliminary observations in 8 patients. J Clin Psychiatry. 2005; 66:49-51.
14. Sumiyoshi T, Higuchi Y, Uehara T. Neural basis for the ability of atypical antipsychotic drugs to improve cognition in schizophrenia. Front Behav Neurosci. 2013;7:140.